Trippier PC

ORCID: 0000-0002-4947-5782 · 2 papers in corpus

review 2026

AKR1C3 inhibitors and exploiters for the treatment and therapeutic monitoring of cancer: a patent review (2020-present)

Expert opinion on therapeutic patents ·doi:10.1080/13543776.2026.2699768

INTRODUCTION: Aldo-keto reductase 1C3 (AKR1C3) is a drug target for the treatment of various androgen‑dependent malignancies, including castration-resistant prostate cancer as well as hematological cancers. The enzyme plays a key role in th…

lab-animal 2023

Aldo-Keto Reductase 1C3 Inhibitor Prodrug Improves Pharmacokinetic Profile and Demonstrates In Vivo Efficacy in a Prostate Cancer Xenograft Model

Journal of medicinal chemistry ·doi:10.1021/acs.jmedchem.3c00732

Aldo-keto reductase 1C3 (AKR1C3) is overexpressed in castration-resistant prostate cancer where it acts to drive proliferation and aggressiveness by producing androgens. The reductive action of the enzyme leads to chemoresistance developmen…